A clinically backed, non-invasive light-based therapy for the eye — targeting dry age-related macular degeneration, dry eye disease, and progressive myopia in children. Coming to both Glimpse locations.
Red light therapy — also called photobiomodulation (PBM) or low-level light therapy (LLLT) — uses specific wavelengths of red and near-infrared light, typically between 590 and 850 nanometers, to stimulate cellular activity in the eye.
At the cellular level, these wavelengths are absorbed by mitochondria — the energy-producing engines inside every cell. The light boosts mitochondrial output, reduces oxidative stress, and improves blood flow in the treated tissue. In retinal and ocular surface cells, that translates to measurable clinical benefits.
It is non-invasive, painless, and quick. Each session is typically under 10 minutes. The light is delivered through a precise, controlled device — not the LED panels you'll find online.
In November 2024, the FDA authorized the Valeda Light Delivery System from LumiThera — the first PBM device approved to treat dry AMD. In the pivotal trial, 63.7% of treated eyes showed significant vision gain at 24 months, with 20% reading approximately two lines further on the standard chart. The progression to geographic atrophy was reduced from 24% (sham) to 6.8% (treated).
Protocol: nine sessions per eye over three to five weeks. Each session is under ten minutes and painless.
Light-based therapies including intense pulsed light (IPL) and low-level red light have become part of modern dry-eye protocols, particularly for patients with meibomian gland dysfunction — the most common cause of chronic dry eye. Treatment can help restore healthy oil flow at the eyelid margin and reduce inflammation, often when artificial tears alone have failed.
Repeated low-level red light therapy (RLRL) at 650nm has been studied extensively as a myopia-control intervention for children. In a recent multicenter randomized clinical trial, children using RLRL twice daily showed axial length changes of −0.06mm versus +0.14mm in the control group. A subset of children experienced axial shortening — effectively reversing progression. We use red light as part of a broader myopia-control plan that may also include Stellest lenses, multifocal contacts, or atropine.
We start with a clinical evaluation to confirm that red light therapy is the right intervention for your specific condition. Not every patient is a candidate — that conversation matters.
You sit comfortably with your eyes positioned in front of the delivery device. The treatment is painless and silent. Most sessions last under ten minutes.
Most clinical protocols involve a course of 9 or more sessions over several weeks, then a maintenance schedule based on your response. We track outcomes objectively with imaging and visual measures.
Light-based therapies are clinically promising but not magic. They work best as part of a comprehensive plan, alongside lens, lifestyle, and nutritional interventions tailored to your specific condition.
If you're a candidate for the FDA-authorized Valeda protocol for dry AMD, we'll tell you. If you're a parent considering RLRL for your child's myopia, we'll walk you through the current evidence, including what we don't yet know about long-term outcomes. If you have chronic dry eye that hasn't responded to other treatments, we'll discuss whether light-based therapy fits your case.
The wrong answer for the wrong patient is what makes integrative care lose credibility. We don't do that here.
Book a consultationWe'll review your case, walk you through the current evidence, and tell you plainly whether you're a good candidate.
